Boditech Med Inc. (KOSDAQ:206640)

Market Cap	237.83B -32.6%
Revenue (ttm)	162.09B +17.3%
Net Income	23.65B -13.2%
EPS	1,091.00 -12.2%
Shares Out	20.34M
PE Ratio	10.71
Forward PE	n/a
Dividend	150.00 (1.27%)
Ex-Dividend Date	Mar 31, 2026

Volume	45,867
Average Volume	43,548
Open	11,860
Previous Close	11,780
Day's Range	11,660 - 11,870
52-Week Range	10,370 - 18,670
Beta	0.45
RSI	48.45
Earnings Date	May 12, 2026

About Boditech Med

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 541
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206640

Financial Performance

In 2025, Boditech Med's revenue was 162.09 billion, an increase of 17.32% compared to the previous year's 138.16 billion. Earnings were 23.65 billion, a decrease of -13.23%.